Clinical trial

CLOZAPINE Response in Biotype-1

NCT04580134

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-03-01

PhasePHASE4

Study timeline

Study start (actual)2022-03-01Date precision: day

Registry last updated2026-05-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Schizoaffective Disorderunresolved

Bipolar 1 Disorderunresolved

Interventions

risperidoneDRUG

Sponsors & collaborators

University of Texas Southwestern Medical Centerlead sponsor

National Institute of Mental Health (NIMH)collaborator

Beth Israel Deaconess Medical Centercollaborator

Hartford Hospitalcollaborator

University of Georgiacollaborator

University of Chicagocollaborator

Mapped research locations

BostonMassachusetts, United States1 ChicagoIllinois, United States1 DallasTexas, United States1 HartfordConnecticut, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04580134 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.